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Abstract - Acute coronary syndrome (ACS)  represents 
the most common cause of death worldwide.  
Percutaneous coronary intervention (PCI) is the 
management of choice in patients with ACS and 
occurrence of intra-procedural thrombotic 
complications are an independent predictor of mortality 
and other major adverse cardiovascular events in 
patients undergoing PCI. According to current 
guideline, anticoagulation therapy is indicated during 
PCI in order to reduce the risk of thrombotic 
complications such as stent thrombosis. Among 
currently available anticoagulant drugs, bivalirudin 
demonstrates a lower incidence of bleeding risk, 
despite it is associated with an increased risk of stent 
thrombosis. The aim of this paper is to discuss the 
pharmacology of bivalirudin and the clinical evidences 
of its use in  patients undergoing PCI for ACS.   
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I. INTRODUCTION 
 
Coronary artery disease (CAD) represents the most 
common cause of death worldwide. According to 
characteristic electrocardiographic modifications, ACS 
are classified in: ST-segment elevation myocardial 
infarction (STEMI), non-ST-segment elevation 
myocardial infarction (NSTEMI) and unstable angina 
(UA) if cardiac biomarkers are negative1. 
PCI is the management of choice  in patients with 
ACS2,3. The occurrence of intraprocedural thrombotic 
complications is an independent predictor of 
cardiovascular mortality and major adverse 
cardiovascular events (MACE) in patients undergoing 
PCI4,5 and, according to current guideline, 
anticoagulation therapy is indicated, during PCI, in 
order to reduce this risk. Unfractionated heparin 
(UFH), low molecular weight heparin (LMWH) and 
fondaparinux, were considered the anticoagulants of 
choice for years, while, recently, bivalirudin, has been 
indicated in patients undergoing PCI6. The 2013 
American College of Cardiology Foundation and 
American Heart Association guideline for management 
of patients with ST segment elevation myocardial 
infarction, recommends UFH with or without planned 
glycoprotein IIb/IIIa inhibitor (GPI) or bivalirudin as 
class I indication for patients undergoing primary PCI, 
with a preference for bivalirudin over UFH plus GPI in 
patients at high risk of bleeding (class IIa)7. The 2012 
European Society of Cardiology guideline, however, 
recommend bivalirudin over UFH plus GPI (class I) 
but also LMWH (with or without GPI) over UFH 
(class IIb)8. Among currently available anticoagulant 
drugs, bivalirudin demonstrates a lower incidence of 
bleeding risk, despite it is associated with an increased 
risk of stent thrombosis. The aim of this paper is to 
discuss the pharmacology of bivalirudin and the 
clinical evidences of its use in  patients undergoing PCI 
for an ACS.   
 
II. PHARMACOLOGY OF BIVALIRUDIN 
 
Bivalirudin is a transient and reversible thrombin 
inhibitor, preventing initiation and continuation of clot 
formation (Figure 1). It is a semi synthetic peptide of 
20-amino acid peptide (2,180 Da molecular weight) 
derived from Irudin and extracted from Hirudo 
medicinalis9, with an half-life of 25 minutes and a 
volume of distribution of 0.24 l/kg; after intravenous 
administration it has a complete and immediate 
bioavailability. Bivalirudin has a lack of binding to 
plasma proteins and about 20% is excreted unmodified 
in the urine; renal failure prolongs its half-time up to 
four hours. No pharmacokinetic modifications have 
been observed in different age or gender10 (Table 1). 
Currently, the recommended dose for patients 
undergoing PCI is a bolus of 0.75 mg/kg followed by 
an infusion of 1.75mg/kg/h for the duration of the 
procedure6. Unfortunately, no specific antidote exists 
for bivalirudin intoxication/overdosage and 
hemodialysis, hemofiltration, or plasmapheresis seem 
to be helpful in case of overdosage11. 
 
Figure 1. The clotting cascade and role of bivalirudin. 
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III. BIVALIRUDIN IN STEMI SETTING 
 
Randomized trials testing the use of bivalirudin in 
STEMI setting are listed in Table 2.  
The first study assessing bivalirudin safety and efficacy 
in STEMI setting was the Harmonizing Outcomes With 
Revascularization and Stents in Acute Myocardial 
Infarction (HORIZONS-AMI), performed in a large 
population of 3602 STEMI patient undergoing primary 
PCI12. The aim of this perspective, open-label, 
multicenter, randomized trial was to evaluate the 
incidence of major bleeding and combined adverse 
clinical events within 30 days of bivalirudin 
administration compared with UFH plus GPI, in 
STEMI patients. Combined adverse clinical events 
were defined as death, reinfarction, target-vessel 
revascularization for ischemia, and stroke. Patients 
were randomly assigned, in an open-label fashion and 
in a 1:1 ratio, to treatment with UFH plus GPI (the 
control group), both started before PCI, or  to treatment 
with bivalirudin alone, administered by intravenous 
bolus of 0.75 mg/kg followed by an infusion of 1.75 
mg/kg/hour discontinued at the completion of PCI. 
About two thirds of patients in the bivalirudin arm 
were pretreated with a UFH bolus before cardiac 
catheterization, and in 7.2% of them GPI were 
administered due to giant thrombus or no reflow after 
PCI.  Patients in  bivalirudin arm had a significantly 
reduced rate of net adverse clinical events (9.2 vs. 
12.1%; relative risk [RR], 0.76; 95% confidence 
interval [CI], 0.63 to 0.92; p=0.005), due to a lower 
rate of major bleeding (4.9 vs. 8.3%; RR, 0.60; 95% 
CI, 0.46 to 0.77; p<0.001), with similar rates of 
MACE. Furthermore, they showed lower 30-days 
mortality (2.1 vs. 3.1%; RR, 0.66; 95% CI, 0.44 to 
1.00; p=0.047), lower non-coronary artery bypass graft 
(CABG)-related bleedings (4.9 vs. 8.3%; p<0.001), 
while an increased risk of acute stent thrombosis was 
observed (1.3% vs. 0.3%, p<0.001). After 1 year, the 
rate of net adverse clinical events was lower in the 
bivalirudin group than in the control group (15.6%vs 
18.3%, hazard ratio [HR] 0.83, 95% CI 0.71-0.97, p= 
0.022), as a result of a lower rate of major bleeding in 
the bivalirudin group (5.8%vs 9.2%, HR 0.61, 0.48-
0.78, p<0.0001). The rate of MACE was similar 
between groups (11.9%vs 11.9%, HR 1.00, 0.82-1.21, 
p=0.98). The 1-year rates of cardiac mortality (2.1%vs 
3.8%, HR 0.57, 0.38-0.84, p=0.005) and all-cause 
mortality (3.5%vs 4.8%, HR 0.71, 0.51-0.98, p=0.037) 
were lower in the bivalirudin group than in the control 
group. The rate of stent thrombosis at 1 year was 
similar in both groups13. These findings were 
confirmed up to 3 years follow-up, when patients in 
bivalirudin arm showed lower rates of all-cause 
mortality (5.9 vs. 7.7%, difference -1.9% [-3.5 to -0.2], 
HR 0.75 [0.58-0.97]; p=0.03), cardiac mortality (2.9 
vs. 5.1%, -2.2% [-3.5 to -0.9], 0.56 [0.40-0.80]; p= 
0.001), reinfarction (6.2 vs. 8.2%, -1.9% [-3.7 to -0.2], 
0.76 [0.59-0.99]; p=0.04), and major bleeding not 
related to bypass graft surgery (6.9 vs. 10.5%, -3.6% [-
5.5 to -1.7], 0.64 [0.51-0.80]; p=0.0001) with no 
significant differences in ischemia-driven target vessel 
revascularisation, stent thrombosis, or composite 
adverse events14.  Taken together these data indicate 
that bivalirudin use during PCI is safe with a 
significant reduction of ischemic adverse events but 
with an increased risk of acute stent thrombosis. A 
further randomized trial comparing bivalirudin, with 
UFH and routine use GPI, the European Ambulance 
Acute Coronary Syndrome Angiography (EUROMAX)  
study was performed. EUROMAX was a randomized, 
international, prospective, open-label ambulance trial 
comparing bivalirudin (0.75 mg/kg bolus followed 
immediately by a 1.75-mg/kg per hour infusion for  
≥30 minutes prior to primary PCI and continued for ≥4 
hours after the end of the procedure at the reduced dose 
of 0.25 mg/kg per hour) with UFH with or without GPI 
in 2200 patients with STEMI undergoing primary PCI. 
The primary end point was the evaluation of the 
incidence of death from any cause or non-CABG-
related major bleeding at 30 days15. Patients in 
bivalirudin arm showed lower rate of death from any 
cause or non-CABG-related major bleeding (5.1 vs. 
8.5%; RR 0.6; 95% CI 0.43–0.82; p=0.001). No 
significant differences in reinfarction rate and all cause 
mortality were observed in both groups. The incidence 
of stent thrombosis was higher in bivalirudin arm in the 
first 24 hours (1.1% vs. 0.2%; RR 6.11, 95% CI 1.37–
27.24, p=0.007), being comparable after 24 hours up to 
30 days. The composite outcome of net adverse clinical 
events (death, reinfarction, ischemia-driven  
revascularization, or stroke) incidence was lower in 
bivalirudin arm (7.8 vs. 10.6%; RR 0.73, 95% CI 0.56–
0.96, p=0.02). This trial confirmed the reduced 
bleeding risk in patients treated with bivalirudin, but, 
despite a prolonged drug administration, the incidence 
of stent thrombosis was still higher in the first 24 hours 
despite the use of more potent thienopyridine agents. 
To test the hypothesis that association of bivalirudin 
plus GPI was superior to bivalirudin alone in reducing 
stent thrombosis, a trial comparing antithrombotic 
therapy with bivalirudin or UFH during PCI, How 
Effective are Antithrombotic Therapies in Primary 
Percutaneous Coronary Intervention (HEAT-PPCI) trial 
was then performed. HEAT-PPCI was an open-label, 
single centre, randomized trial, in which 1812 STEMI 
patients were randomized (1:1; stratified by age [<75 
years vs ≥75 years] and presence of cardiogenic shock 
[yes vs no]) to UFH (70 U/kg) or bivalirudin (bolus 
0.75 mg/kg; infusion 1.75 mg/kg/h for the duration of 
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the procedure). Primary efficacy outcome, defined as  a 
composite of all-cause mortality, cerebrovascular 
accident, reinfarction, or unplanned target lesion 
revascularisation, and primary safety,  defined as 
incidence of major bleeding were evaluated at 28 
days16. GPI was administered with no significant 
differences in both groups, in presence of massive 
thrombus, slow or no-reflow, or a thrombotic 
complication (13% in the bivalirudin and 15% in the 
UFH group). The primary efficacy outcome at 28 days 
was prevalent in bivalirudin arm (8.7 vs. 5.7%; RR 
1.52, 95% CI 1.09–2.13, p=0.01). Bivalirudin patients 
showed an higher reinfarction and revascularization 
rate (2.7 vs. 0.9%, p=0.004; 2.7 vs. 0.7%, p=0.001, 
respectively). These findings may be explained with 
the abrupt discontinuation of bivalirudin infusion as 
soon as angioplasty was terminated, thus increasing the 
incidence of stent thrombosis (3.4 vs. 0.9%, p= 0.001). 
No significant differences were observed in both 
groups in the primary safety outcome at 28 days. In 
order to evaluate efficacy and safety of the association 
between bivalirudin and prasugrel, compared with 
UFH and clopidogrel the Bavarian Reperfusion 
Alternatives Evaluation (BRAVE) 4 study  was 
performed. BRAVE 4 was a randomized, open-label, 
multicenter trial, comparing prasugrel plus bivalirudin 
to clopidogrel plus UFH in 548 STEMI patients 
planned for primary PCI17. Aim of this study was test 
the hypothesis that in STEMI patients undergoing 
primary PCI, prasugrel plus bivalirudin therapy is 
superior to clopidogrel plus heparin in terms of net 
clinical outcome (the composite of death, recurrent 
myocardial infarction, unplanned infarct-related artery 
revascularization, stroke, definite stent thrombosis, or 
major bleeding).  No significant difference between 
two groups in the composite ischemic endpoint, 
bleeding events, cardiac mortality, or definite stent 
thrombosis, were observed and, due to slow 
recruitment, the trial was prematurely stopped. The 
Bivalirudin in Acute Myocardial Infarction vs Heparin 
and GPI Plus Heparin Trial (BRIGHT) was performed 
to determine if bivalirudin is superior to UFH with or 
without tirofiban during primary PCI. BRIGHT was a 
multicenter, open-label, randomized trial, involving 
2194 patients with acute myocardial infarction 
undergoing primary PCI (1925 patients with STEMI 
and 269 patients with NSTEMI). Patients were 
randomly assigned to receive bivalirudin with a post-
PCI infusion (n = 735), heparin alone (n = 729), or 
UFH plus tirofiban with a post-PCI infusion 
(n = 730)18. Aim of the study was to determine if 
bivalirudin was superior to UFH alone or  plus 
tirofiban during primary PCI in term of composite of 
all-cause mortality, reinfarction, target vessel 
revascularization, stroke, and any bleeding events at 30 
days. Net adverse clinical events in patients treated 
with bivalirudin, UFH and UFH plus tirofiban were 
8.8%, 13.2% and 17%, respectively (RR for bivalirudin 
vs. UFH 0.67, 95% CI 0.50–0.90, p=0.008). This 
finding was largely due to a reduction in bleeding 
events with bivalirudin, while no significant 
differences in major adverse cardiac, cerebral events or 
stent thrombosis among three groups were observed. 
Taken together these data demonstrated a lower 
incidence of bleeding with bivalirudin without any 
reduction on mortality. The Minimizing Adverse 
Haemorrhagic Events by TRansradial Access Site and 
Systemic Implementation of angioX (MATRIX) was a 
randomised, multicentre trial comparing transradial 
against transfemoral access in patients with ACS 
undergoing PCI. Patients were randomized (1:1) to 
radial or femoral access and to receive bivalirudin, 
stopped at the end of PCI or prolonged infusion for at 
least 4–6 hours, or UFH with provisional GPI19. The 
primary outcome was the composite of death, non-fatal 
myocardial infarction, or stroke, evaluated at 30 days. 
No significant differences were observed in patients 
treated with bivalirudin compared to patients treated 
with UFH (10.3 vs. 10.9%, p=0.45). Furthermore, 
patients in bivalirudin arm showed a lower rate of 
bleeding but an higher rate of stent thrombosis (1.4 vs. 
2.5%, p=0.001; 1 vs. 0.6%, p=0.048, respectively). 
Interestingly, patients in bivalirudin arm showed lower 
rate of all cause mortality (1.7 vs. 2.3%, p=0.042). 
Thus, despite several randomized studies, the safety 
and efficacy of bivalirudin compared with UFH, with 
or without GPI, in patients with acute myocardial 
infarction undergoing PCI are still uncertain. Among 
all these randomized trials, bivalirudin showed a 
significant reduction of bleeding rate with an higher 
incidence of early stent thrombosis. However, when 
bivalirudin was administered up to 4 hours after the 
end of PCI, as in the BRIGHT trial, no differences in 
the incidence of early stent thrombosis were observed 
between bivalirudin and UFH arms, suggesting that a 
prolonged bivalirudin administration may significantly 
reduces the incidence of early stent thrombosis. 
Furthermore, as demonstrate in the EUROMAX trial, 
prolonging the low dose bivalirudin administration 
after PCI, reduces incidence of major bleeding, with a  
reduction in the overall mortality rate but an increased 
risk of stent thrombosis within the first 24 hrs post PCI. 
This finding is confirmed in our experience in more 
than 600 STEMI patients undergoing PCI and 
prolonged bivalirudin administration up to 40 hours 
after PCI (unpublished data). 
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IV. BIVALIRUDIN IN NSTEMI SETTING 
 
Randomized trials testing the use of bivalirudin in 
NSTEMI setting are listed in Table 3.  
The Acute Catheterization and Urgent Intervention 
Triage Strategy (ACUITY)  was a prospective, open-
label trial, enrolling patients with moderate- or high-
risk NSTE-ACS, with a prevalence of NSTEMI 
patients (59%)20. This study compared three different 
therapeutic strategies: UFH or enoxaparin plus GPI, 
bivalirudin plus GPI, or bivalirudin alone (with 
provisional use of GPI during PCI). All patients 
underwent coronary angiography within 72 h after 
randomization (median of 19.5–19.8 h). Patients on 
GPI had a further randomization in a two-by-two 
factorial design to receive the GPI either immediately 
after randomization (upstream) or to defer 
administration in the cath-lab at PCI starting. The 
endpoints of composite ischemia (death, myocardial 
infarction, or unplanned revascularisation for 
ischemia), major bleeding, and net clinical outcomes 
(combining composite ischemia or major bleeding), 
were evaluated at 30-day. There were no significant 
differences in the rate of primary or secondary 
outcomes evaluated at 30 days between patients who 
receiving bivalirudin plus GPI and patients treated by 
UFH plus GPI (composite ischemia rate: 9 vs. 8%, p= 
0.16; major bleeding: 8 vs. 7%, p=0.32; net clinical 
outcomes: 15 vs. 13%, p=0.1). Rates of composite 
ischemia were similar in those who received 
bivalirudin alone and those who received UFH plus 
GPI (9 vs. 8%, p=0.45); however, patients who 
received bivalirudin showed a significantly reduction 
of major bleeding, compared to UFH plus GPI group (4 
vs. 7%, p<0.0001, RR 0.52, 95% CI 0.40-0.66), 
resulting in a trend towards better 30-day net clinical 
outcomes (12 vs. 13%, p=0.057; 0.87, 0.75-1.00). 
Furthermore, this trial demonstrated that transradial 
intervention compared to femoral arterial access was 
able to reduce major bleeding complication. Similar 
results were observed at 1 year follow-up21. No 
differences were observed in the composite endpoint of 
ischemia or all cause mortality as well as in deferred 
selective use of GPI compared with routine upstream 
use. The Randomized Trial to Evaluate the Relative 
PROTECTion against Post-PCI Microvascular 
Dysfunction and Post-PCI Ischemia among Anti-
Platelet and Anti-Thrombotic Agents–Thrombolysis In 
Myocardial Infarction-30 (PROTECT–TIMI-30) was 
performed to evaluate GPI inhibition with eptifibatide 
when administered with indirect thrombin inhibition as 
compared to monotherapy with direct thrombin 
inhibition with bivalirudin among patients with 
NSTEMI. The PROTECT TIMI-30 was a randomized 
trial enrolling patients presenting with NSTE-ACS who 
had at least one of this risk factors (diabetes mellitus, 
positive cardiac biomarkers, ST-segment deviation > 
0.5 mm, TIMI risk score ≥ 3) and were anticipated to 
undergo PCI22. Patients were randomized in three 
groups: UFH plus eptifibatide, enoxaparin plus 
eptifibatide or bivalirudin with provisional eptifibatide. 
No significant difference were observed between 
bivalirudin and both eptifibatide arms in the composite 
of death, myocardial infarction, or ischemia on Holter 
through 48 h, or the rate of TIMI major bleeding. The 
combination of GPI and UFH has not been compared 
with bivalirudin in NSTEMI patients and the 
Intracoronary Stenting and Antithrombosis Research- 
Rapid Early Action for Coronary Treatment  (ISAR –
REACT) 4 was performed to evaluate which treatment 
is more effective to prevent thrombotic and bleeding 
complications. ISAR-REACT 4 was a double blind 
double-dummy trial comparing UFH plus abciximab 
with bivalirudin in patients undergoing PCI due to 
NSTEMI23. All patients received 325–500 mg of 
aspirin and 600 mg of clopidogrel. The primary 
outcome, a composite of death, large recurrent 
myocardial infarction, urgent target-vessel 
revascularization, or major bleeding within 30 days, 
was similar in two groups (10.9 vs. 11%, p=0.94; RR 
0.99, 95% CI 0.74–1.32). Death, any recurrent 
myocardial infarction, or urgent target-vessel 
revascularization were similar in both groups (12.8 vs. 
13.4%, p=0.76; RR 0.96; 95% CI, 0.74 to 1.25). Major 
bleeding was prevalent in the abciximab group ( 4.6 vs. 
2.6%, p=0.02; RR 1.84; 95% CI, 1.10 to 3.07). This 
study showed that abciximab and unfractionated 
heparin, as compared with bivalirudin, failed to reduce 
the rate of the primary end point and increased the risk 
of bleeding among patients with non-ST-segment 
elevation myocardial infarction undergoing PCI. These 
findings were confirmed at 1 year follow-up24.  To 
evaluate the optimal adjunctive anticoagulation 
regimen for PCI in patients presenting ACS initially 
treated with fondaparinux, the SWITCH III trial was 
performed. SWITCH III was an open-label pilot trial 
comparing UFH to bivalirudin in patients presenting 
with ACS initially treated with fondaparinux and a 
Translational Medicine @ UniSa - ISSN 2239-9747 2016, 14(9): 54-63
 
58 
Università degli Studi di Salerno 
loading dose of 600 mg of clopidogrel25. During PCI, 
patients were randomized to either bivalirudin or UFH 
therapy in a 1:1 fashion. GPI were used in 3.9% 
patients of bivalirudin and 12.2% patients of UFH 
group. The number of ischemic or bleeding events was 
very low and no significant differences were detected 
between groups. Current data suggest that bivalirudin 
treatment, compared to others anticoagulant drugs, in 
NSTEMI patients underwent PCI results in bleeding 
reduction with no differences in the rate of death, 
myocardial infarction or recurrent ischemia.  
 
 
 
V. BIVALIRUDIN IN STABLE OR UNSTABLE 
ANGINA SETTING 
 
Randomized trials testing the use of bivalirudin in the 
management of stable or unstable angina are listed in 
Table 4.  
The HIRULOG was a double blind trial enrolling 
patients with unstable angina or post-infarction angina 
undergoing urgent PCI26. Patients were randomized in 
two groups receiving either heparin or bivalirudin 
immediately before angioplasty. The primary end point 
was in hospital death, myocardial infarction, abrupt 
vessel closure, or rapid clinical deterioration of cardiac 
origin. Patients receiving bivalirudin did not show a 
significant reduction of the incidence of the primary 
end point (11.4 vs. 12.2%, p=0.26) but a significant 
lower incidence of bleeding (3.8 vs. 9.8%, p<0.001). 
After this trial, bivalirudin was approved for use in 
Europe and the United States as an alternative to UFH 
for patients with unstable angina during PCI. To 
determine the efficacy of bivalirudin compared with 
UFH plus GPI at 6 months and 1 year, the Randomized 
Evaluation in PCI Linking Angiomax to Reduced 
Clinical Events (REPLACE)-2 trial was performed27. 
Patients were randomized to receive intravenously 
bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for 
the duration of PCI), with provisional GPI, or to 
receive UFH (65 U/kg bolus) with planned GPI 
(abciximab or eptifibatide). Patients undergoing PCI 
due to acute myocardial infarction were excluded. The 
primary end point was defined as  a composite of 
death, myocardial infarction, severe ischemia requiring 
surgical or percutaneous revascularization, or major 
bleeding at 30 days. No significant differences were 
observed between groups in death, myocardial 
infarction and repeat revascularization (1.4 vs. 1%; 
HR, 0.70; 95% CI, 0.43-1.14; p=0.15; 7.4 vs. 8.2%; 
HR, 1.12; 95% CI, 0.93-1.34; p=0.24; 11.4 vs. 12.1% 
HR, 1.06; 95% CI, 0.91-1.23; p=0.45; respectively). 
Patients in bivalirudin arm showed a significant 
reduction of major bleeding (2.4 vs. 4.1%, p<0.001). 
Long-term (6 and 12 months) clinical outcomes were 
similar in both groups. The Authors concluded that 
bivalirudin was non-inferior to UFH/GPI concerning 
the acute ischemic end points and was associated with 
a lower rate of major bleeding. To assess the 
superiority of bivalirudin compared with UFH in 
patients with stable or unstable angina who undergo 
PCI after pretreatment with clopidogrel the 
Intracoronary Stenting and Antithrombosis Research - 
Rapid Early Action for Coronary Treatment (ISAR –
REACT) 3 study was performed. ISAR-REACT 3 was 
a multicenter double-blind randomized trial, designed 
to compare bivalirudin with UFH in patients 
undergoing PCI for stable or unstable angina28. The 
aim of this study was to compare bivalirudin with UFH 
in patients who had stable or unstable angina pectoris 
undergoing PCI and stenting after pretreatment with 
600 mg of clopidogrel and aspirin (325 to 500 mg). 
The primary end point was the composite of death, 
myocardial infarction, urgent target-vessel 
revascularization due to myocardial ischemia within 30 
days after randomization, or major bleeding during the 
index hospitalization (with a net clinical benefit 
defined as a reduction in the incidence of the end 
point). The secondary end point was the composite of 
death, myocardial infarction, or urgent target-vessel 
revascularization. No significant differences were 
observed between groups in primary and secondary 
end point (8.3 vs. 8.7%; RR, 0.94; 95% CI, 0.77 to 
1.15; p=0.57; 5.9 vs. 5.0%; RR 1.16; 95% CI, 0.91 to 
1.49; p=0.23). The incidence of major bleeding was 
prevalent in UFH group (3.1 vs. 4.6%; RR, 0.66; 95% 
CI, 0.49 to 0.90; p=0.008). In conclusion, in patients 
with stable and unstable angina undergoing PCI after 
preloading with clopidogrel, bivalirudin did not 
provide a net clinical benefit, but significantly reduced 
the incidence of major bleeding. The Novel 
Approaches for Preventing or Limiting EventS 
(NAPLES) trial was performed to evaluate bivalirudin 
safety and efficacy in the high risk subset of diabetic 
patients undergoing PCI. NAPLES was a single centre 
randomized trial focusing on the management of 
diabetic patients undergoing elective PCI pretreated 
with a loading dose of clopidogrel of 300 mg29. 
Patients were randomized to receive bivalirudin 
monotherapy or UFH plus routine tirofiban. The 
primary composite end point (30-day composite 
incidence of death, urgent repeat revascularization, 
myocardial infarction, and all bleedings) was lower in 
the bivalirudin group (18.0% vs. 31.5%, OR 0.47, 95% 
CI 0.28 to 0.79, p=0.004). No death, urgent 
revascularization, or Q-wave myocardial infarction 
were observed. The rate of non-Q-wave myocardial 
infarction was similar in the 2 groups (10.2 vs. 12.5%, 
p=0.606). A lower rate of any bleeding was observed in 
bivalirudin arm (8.4 vs. 20.8%, OR 0.34, 95% CI 0.18 
to 0.67, p=0.002). This difference was mainly ascribed 
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to the lower rate of minor bleeding (7.8 vs. 18.5%, OR 
0.37, 95% CI 0.19 to 0.74, p=0.005), although the rate 
of major bleeding in the 2 groups was similar (0.6 vs. 
2.4%,  p=0.371). In conclusion, in patients with 
diabetes undergoing elective PCI, bivalirudin allows a 
reduction of in-hospital bleeding. To evaluate the 
effectiveness of bivalirudin versus UFH in selected PCI 
patients at high bleeding risk the Anti-Thrombotic 
Strategy for Reduction of Myocardial Damage During 
Angioplasty-Bivalirudin vs Heparin (ARMYDA-7 
BIVALVE) was performed. ARMYDA-7 BIVALVE 
was a randomized open-label trial in patients at high 
bleeding, due to age >75 years, chronic renal failure, 
and diabetes mellitus, with documented coronary artery 
disease undergoing PCI risk30. Patients were 
randomized to bivalirudin (bolus 0.75 mg/kg followed 
by infusion during the procedure; n = 198) or UFH (75 
IU/kg; n = 203), with provisional use of GPI during 
PCI. Patients undergoing primary PCI for STEMI were 
excluded. The primary efficacy and safety end point 
were the 30-day incidence of major adverse cardiac 
events (cardiac death, myocardial infarction, stent 
thrombosis, or target vessel revascularization), and the 
occurrence of any bleeding or entry-site complications 
after PCI, respectively. All patients were preloaded 
with clopidogrel 600 mg. No statistically significant 
differences between two groups were observed in 
major adverse cardiac event rate at 30 days (11.1 vs. 
8.9%, p=0.56). The occurrence of the primary safety 
end point was lower in bivalirudin group (1.5 vs. 9.9%; 
p= 0.0001) and, this benefit, was essentially driven by 
the prevention of entry-site hematomas >10cm (0.5% 
vs. 6.9%, p=0.002). In conclusion, bivalirudin induces 
significantly lower bleeding and has a similar 
incidence of major adverse cardiac events in elderly 
patients, in patients with diabetes mellitus, or chronic 
renal failure undergoing PCI. Novel Approaches in 
Preventing and Limiting Events III Trial: Bivalirudin in 
High-Risk Bleeding Patients (NAPLES) III study 
assessed the safety and the efficacy of bivalirudin 
compared with UFH alone in the subset of patients at 
increased risk of bleeding undergoing elective PCI by 
femoral access. NAPLES III was a single-center 
double-blind trial comparing UFH to bivalirudin in 
patients undergoing elective PCI who had negative 
biomarkers but an high bleeding risk31. The primary 
endpoint was the rate of in-hospital major bleeding and 
no significant differences were observed among two 
groups (2.6 vs. 3.3%; p=0.54). The results of this 
randomized study suggested that there was no 
difference in major bleeding rate between bivalirudin 
and UFH in increased-risk patients undergoing 
transfemoral PCI.   
As suggested by latest ESC guideline on myocardial 
revascularization among PCI patients with negative 
biomarkers, bivalirudin reduced bleeding without 
affecting mortality and might therefore be considered 
for use in patients at high risk for bleeding32. 
 
 
 
VI. META-ANALYSES 
 
Several meta-analyses have been recently published in 
order to clarify the role of bivalirudin for patients 
undergoing PCI in different setting of patients. 
Cavender and Sabatine performed a meta-analysis of 
16 studies enrolling patients for planned PCI and 
randomly assigned to bivalirudin or heparin (UFH or 
low-molecular weight heparin) with or without a GPI33. 
The primary efficacy endpoint was the incidence of 
major adverse cardiac events up to 30 days. Secondary 
efficacy endpoints were death, myocardial infarction, 
ischemia-driven revascularisation, and stent 
thrombosis. The primary safety endpoint was major 
bleeding up to 30 days. Bivalirudin use was associated 
with an high risk of major adverse cardiac events (RR 
1.09, 95% CI 1.01-1.17; p=0.0204), driven by an 
increases in myocardial infarction (1.12, 1.03-1.23) and 
ischaemia-driven revascularisation (1.16, 0.997-1.34) 
as compared with heparin, with no effect on mortality 
(0.99, 0.82-1.18). Furthermore, bivalirudin patients 
showed an increased risk of stent thrombosis (RR 1.38, 
95% CI 1.09-1.74; p=0.0074), which was primarily due 
to an increase in acute cases in ST-segment elevation 
myocardial infarction (4.27, 2.28-8.00; p<0.0001). 
Moreover, bivalirudin patients showed lower major 
bleeding risk (RR 0.62, 95% CI 0.49-0.78; p<0.0001), 
but the magnitude of this effect varied greatly 
(p<0.0001) depending on whether GPI were used 
predominantly in the UFH arm only (0.53, 0.47-0.61; 
p<0.0001), provisionally in both arms (0.78, 0.51-1.19; 
p=0.25), or planned in both arms (1.07, 0.87-1.31; p= 
0.53). In conclusion, the use of bivalirudin increases 
the risk of myocardial infarction and stent thrombosis, 
but decreases the risk of bleeding, with the magnitude 
of the reduction depending on concomitant GPI use. 
Current recommendations on the use of bivalirudin in 
patients treated with PCI are mostly based on trials 
comparing bivalirudin versus UFH plus planned GPI. 
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Whether bivalirudin is also superior to UFH alone is 
still not well established. A meta-analysis of Cassese et 
al. investigates the efficacy and safety of bivalirudin 
versus UFH in patients treated with PCI without 
planned use of GPI34. The primary efficacy and safety 
outcomes were the 30-day incidence of death and 
major bleeding, respectively. The secondary outcomes 
were the 30-day incidence of myocardial infarction, 
definite stent thrombosis, urgent target vessel 
revascularization, and overall death at the longest 
available follow-up. Odds ratio (OR) and 95%CI  
served as summary statistics. At 30 days, bivalirudin 
versus UFH showed a comparable risk of death (1.09 
[0.83-1.41], p=0.54), and myocardial infarction (1.10 
[0.83-1.46], p=0.50) with a trend towards a higher risk 
of urgent target vessel revascularization (1.37 [0.96-
1.96], p=0.08). The risk of major bleeding was lower 
with bivalirudin (0.57 [0.40-0.80], p=0.001) and the 
bleeding reduction was more evident when high doses 
of UFH were used as comparator (p for interaction 
<0.001). The risk of definite stent thrombosis (2.09 
[1.26-3.47], p=0.005) and, in particular, the risk of 
acute stent thrombosis (3.48 [1.66-7.28], p< 0.001) was 
increased by bivalirudin. In conclusion, patients 
undergoing PCI randomised to therapy with either 
bivalirudin or UFH showed a similar mortality. 
Bivalirudin appears to reduce the risk of major 
bleeding at the expense of a higher risk of acute stent 
thrombosis. The evaluation of early stent thrombosis 
with bivalirudin in patients undergoing PCI still 
unclear. Piccolo et al. performed a meta-analysis of 
randomized trials assessing the risk of early ST 
associated with bivalirudin as compared to other 
antithrombotic regimens in patients undergoing PCI35. 
Compared to other regimens, bivalirudin significantly 
increased the risk of early stent thrombosis (OR= 1.80; 
95 % CI, 1.28-2.52; p=0.0007) and reduced the risk of 
major bleeding (OR [95 %CI]=0.64 [0.51-0.82], 
p=0.0003), with a comparable risk of mortality or 
myocardial infarction. The higher risk of early stent 
thrombosis was mainly due to acute (OR [95 % CI] 
=4.33 [2.33-8.05], p<0.001) rather than subacute (OR 
[95 % CI] =0.89 [0.53-1.50], p=0.67) ST events (p for 
interaction < 0.001). Non-fatal myocardial infarction 
was the most common presentation (83 %) of early 
stent thrombosis events, while death occurred 
infrequently (about 5 %). In conclusion, in patients 
undergoing PCI, bivalirudin compared to UFH is 
associated with a higher risk of early stent thrombosis, 
which is mainly related to more frequent acute events. 
Further studies are required to evaluate alternative 
strategies to mitigate this risk, without hampering the 
benefits derived from the reduction in bleeding events 
with bivalirudin. These meta-analyses substantially 
confirmed a reduction of bleeding, without a 
significant reduction of mortality rate in patients 
treated with bivalirudin; however a re-evaluation of 
current data adding MATRIX study patients 
demonstrate for the first time highly significant 
benefits of radial access in acute coronary syndrome 
patients for major adverse cardiovascular events (p= 
0.0051) and all-cause mortality (p= 0.0011) in patients 
treated with bivalirudin19. In a recent meta-analysis, 
performed by Bavry AA et al. patients treated with 
bivalirudin, compared with those treated with UFH, 
showed a reduction of bleedings rate, but this 
difference was less significative when UFH dosage 
during PCI was reduced, or, when ACT control in the 
cathlab was performed for both study groups (UFH and 
Bivalirudin)35. Finally, as proposed by Navarese et al, 
comparing several anticoagulant regimen, a different 
approach based on an individualized hemorrhagic or 
ischemic risk assessment should be evaluate, 
performing a tailored therapy36. 
 
VII.  CONCLUSIONS 
 
It is widely demonstrated that the use of bivalirudin in 
patients undergoing PCI due to acute coronary 
syndrome or stable angina significantly reduces 
incidence of major bleeding; however it is associated 
with a higher risk of early stent thrombosis, which is 
mainly related to more frequent acute events. MATRIX 
results, for the first time, demonstrated that death for 
all causes was reduced in patients treated with 
bivalirudin after a radial access. BRIGHT trial 
demonstrated that a prolonged bivalirudin 
administration significantly reduced the incidence of 
the early stent thrombosis.  Further randomized clinical 
trials are needed to evaluate the safety and efficacy of  
bivalirudin in the era of PCI through radial artery with 
the use of new P2Y12 inhibitors and bioadsorbable 
scaffold even in high bleeding risk patients in which 
bivalirudin seems to be safe as reported in some case 
report37. Future approaches should be based on patient 
risk stratification in order to choose the best therapeutic 
option in each case with particular regard to the 
prevention of stent thrombosis. Finally, bivalirudin has 
higher cost compared to unfractionated heparin and it 
should be considered in the actual scenario of limited 
financial resources. 
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